STOCK TITAN

eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference in New York, NY. The Company's CEO will discuss the clinical development pipeline and corporate strategy on November 15 at 12:40 PM ET. A live webcast of the event will be available on the Company's website.
Positive
  • None.
Negative
  • None.

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.

Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will participate in a fireside chat discussion of the Company’s clinical development pipeline and corporate strategy to be held on Wednesday, November 15 at 12:40 PM ET.

A live webcast of the event will be available on the "Events and Presentations" page of the Investors section of the Company’s website with a replay available for 90 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT-mTOR and RAS-MEK-ERK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

     
Contacts:    
     
Investors:     Media:
Christopher M. Calabrese
Managing Director
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com
  Kevin Gardner
Managing Director
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com
  Mike Tattory
Account Supervisor
LifeSci Communications
609-802-6265
mtattory@lifescicomms.com


FAQ

What is eFFECTOR Therapeutics, Inc. participating in?

eFFECTOR Therapeutics, Inc. is participating in the 2023 Stifel Healthcare Conference.

Who will be speaking at the fireside chat discussion?

Steve Worland, Ph.D., the president and CEO of eFFECTOR Therapeutics, Inc., will be speaking at the fireside chat discussion.

What will be discussed at the fireside chat discussion?

The fireside chat discussion will focus on the Company's clinical development pipeline and corporate strategy.

When will the fireside chat discussion take place?

The fireside chat discussion will take place on Wednesday, November 15 at 12:40 PM ET.

Where can I watch a live webcast of the event?

A live webcast of the event will be available on the 'Events and Presentations' page of the Investors section of the Company's website.

Will there be a replay of the event?

Yes, a replay of the event will be available for 90 days following the event.

Where can I find more information?

For more information, please visit investors.effector.com.

EFFECTOR THERAPUTCS INC

OTC:EFTR

EFTR Rankings

EFTR Latest News

EFTR Stock Data

611.57k
4.57M
2.91%
6.31%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH